COINFIRM
Coinfirm, the leading crypto AML compliance and illicit asset tracing solution provider, is announcing the expansion of the Atomic AML Oracle to cover an additional 8 blockchains, further strengthening subscribers’ crypto compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005633/en/
Coinfirm AML Oracle (Graphic: Business Wire)
In line with the FATF’s (Financial Action Task Force’s) recommendations, published in its Updated Guidance for a Risk-Based Approach to Virtual Assets and Virtual Asset Service Providers document in October of 2021, DeFi operators are to be viewed as Virtual Asset Service Providers (VASPs). In response to this move, Coinfirm created the Atomic AML Oracle.
An ever-increasing number of national regulators are looking to place decentralised finance (DeFi) firmly under their respective anti-money laundering remits, to continue combatting terrorism financing, fraud, scams and other illicit activities. Along with the FATF, these organisations include the CFTC and the SEC in the U.S., whereas recommendations published in documents like MiCA (Markets in Crypto Assets) published by the European Commission will set the tone for DeFi regulation in the EU.
The new blockchains to be covered by the AML Oracle are the Abitrum, Avalanche, BNB Smart Chain (BSC), Celo, Fantom, Optimism and Polygon chains. Coming soon to the Atomic AML Oracle will be the implementation of the Ethereum Classic and RSK blockchains, further increasing its reach.
The number of addresses blacklisted – covering the OFAC sanctions lists, terrorism financiers, narcotics traffickers, arms dealers, major recent hacker wallets, and other high-risk flags – by the service has grown steadily to encompass 1,000 on each blockchain supported by the Atomic AML Oracle. Batches of ca. 20 addresses are added to the blacklist per week as they are added to the OFAC sanctions list and numerous other global databases listing bad actors’ addresses – continuously curtailing their ability to operate in the crypto space.
The Oracle has been generating increasing user interest since the launch of the Oracle on Ethereum in May of 2022 – so the Oracle’s freemium trial has now ended. To continue gleaning deep, risk-mitigating insights from the Atomic AML Oracle, contact Coinfirm for a monthly subscription and licence.
About Coinfirm
Coinfirm is the world leader in blockchain analytics and RegTech solutions, creating a safer blockchain economy – by protecting entities from being tainted with funds originating from illicit activities like ransomware hacks, human trafficking and terrorist financing – through risk scoring entities, addresses and transactions.
The company, using 350+ proprietary risk algorithms while monitoring 25k+ blockchain entities, provides seamless, scalable tools to comply with stringent regulatory requirements for both CeFi and DeFi.
Founded in 2016, Coinfirm is headquartered in the UK, with the company retaining offices in Poland, Canada, France and Japan. Over 300 entities have trusted the company to provide RegTech solutions.
For more information visit: www.coinfirm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005633/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t
Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release
AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe
SLB Announces Third-Quarter 2025 Results17.10.2025 12:50:00 CEST | Press release
Revenue of $8.93 billion increased 4% sequentially and decreased 3% year on year GAAP EPS of $0.50 decreased 32% sequentially and 40% year on year EPS, excluding charges and credits, of $0.69 decreased 7% sequentially and 22% year on year Net income attributable to SLB of $739 million decreased 27% sequentially and 38% year on year Adjusted EBITDA of $2.06 billion was flat sequentially and decreased 12% year on year Cash flow from operations was $1.68 billion and free cash flow was $1.10 billion, including $153 million of acquisition-related payments Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024Se
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release
One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select
Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release
Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom